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Abstract 
For the sake of exploring a safe and effective immune potentiator to promote the immune responses of swine to 
Pseudorabies vaccine, the chitosan nanoparticles (CNP) were prepared by use of ionotropic gelation method to 
encapsulate the recombinant VR1020 eukaryotic plasmids which respectively containing pig interleukin-6 gene 
(VPIL6) and the combination of PIL-6 gene and immunostimulatory sequences consisted of 11 CpG motifs (VPIL6C), 
designated respectively as VPIL6-CNP and VPIL6C-CNP. Then forty 21-day-old hybrid piglets were divided into 
four groups and intramuscularly injected respectively with 0.5mg the VPIL6C-CNP, VPIL6-CNP, CpG and VR1020-
CNP together with the attenuated Pseudorabies vaccine. The bloods were collected from the vaccinated piglets to 
detect the changes of immunoglobulin, specific antibody, IL-2, IL-4, IL-6, IFN-  and immune cells. The results were 
found that in comparison with the control groups with VR1020-CNP, the content of immunoglobulin, and specific 
antibody significantly increased  in the sera from the VPIL6C-CNP and VPIL6-CNP groups from 14 to 56 days post 
inoculation (P<0.05),  and so did the level of IL-2, IL-4, IL-6 and IFN-  of the treated groups. Meanwhile, the number 
of lymphocytes and monocytes also markedly elevated in the treated groups (P<0.05). The immune responses of 
VPIL6C-CNP piglets were notably stronger than group VRIL6-CNP and VRCpG. These suggested that VPIL6C-CNP 
could significantly enhance the immunity of piglets to Pseudorabies vaccine and is a promising effective adjuvant to 
promote the protection of pig against Pseudorabies. 
© 2012 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of ISV  
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1. Introduction 
Pseudorabies is a viral disease in swine that is endemic in most parts of the world. It is caused by porcine 
herpesvirus 1, which is also called Pseudorabies virus (PRV) or suid herpesvirus-1 (SHV-1) and is also known as 
Aujeszky's disease, and in cattle as mad itch. PRV is considered to be the one of most economically important viral 
disease of swine in areas where hog cholera has been eradicated [1]. Research on PRV in pigs has pioneered animal 
disease control with genetically modified vaccines. PRV is now extensively studied as a model for basic processes 
during lytic herpesvirus infection, and for unraveling molecular mechanisms of herpesvirus neurotropism[2,3] . 
Up-to-date, genes of interleukins, interferons, and granulocyte- macrophage colony stimulating factors (GM-CF) 
have been found to be the promising adjuvant due to their safety and effectiveness [4,5]. Interleukin-6 (IL-6) is a vital 
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have been found to be the promising adjuvant due to their safety and effectiveness [4,5]. Interleukin-6 (IL-6) is a vital 
cytokine to modulate the immunity in vaccination and cancer therapy due to their capability to elevate the 
differentiation and maturation of T lymphocytes, which can produce interleukin-2 to enhance the multiple bioactivities 
of many different kinds of cells [7]. Pig IL-6 gene was ever proved to be able to potentiate the immune responses of 
animal[8]. 
Many researches have been focused on exploring new effective adjuvant to improve the immunity of animals to 
genetic vaccines, however, little work about the effect of recombinant of pig IL-6 gene and CpG on the immune 
responses of pigs has been reported. We carried out the present experiment to evaluate the effect of a 
oligodeoxynucleotides containing 11 CpG motifs and the eukaryotic plasmid of pig IL-6 gene in vivo on immunity of 
piglets to Pseudorabies vaccine in order to develop a safer and more efficient immunoadjuvant for animal against 
Pseudorabies. 
2.  Materials and methods 
2.1 Conventional vaccine 
The attenuated Pseudorabies vaccine (produced by Chengdu Medicine and Appliances Factory, China) was used in 
this experiment as a conventional vaccine. One dose for pig vaccination includes the equivalent of 2×109 PFU/ml of 
an inactivated strain of Pseudorabies virus, which is extensively utilized to intramuscularly immunize swine in China 
to prevent Pseudorabies diseases. 
Recombinant PIL-6 gene and PIL-6C eukaryotic expression plasmids  
Construction of VP 1020 recombinant eukaryotic expression plasmids containing pig IL-6 genes  and / or 
oligodeoxynucleotides of 11 CpG motifs were previously prepared in our lab[9]. 
2.2 Large-scale preparation of plasmid DNA  
A single colony recombinant DH5a E.coli, containing VPIL6C, VPIL6 or VR1020 plasmid, was inoculated in LB 
broth with kanamycin at 37 C overnight. Bacterial cells were pelleted by centrifugation and plasmid was extracted 
following the spermine precipitation method [6]. Then the plasmid was resuspended in sterile water and stored at -
20 C until use.  
2.3 Preparation and detection of chitosan nanoparticles (CNP) 
Chitosan was provided by Chengdu Organic Chemistry Institute of Chinese Academy of Science (Sichuan 
province, China), its molecular weight is 150 kD and deacetyl degree is over 95 percent. The chitosan nanoparticles 
(CNP) were prepared by ionotropic gelation method to entrap the VPIL6C (VPIL6C-CNP), VPIL6 (VPIL6-CNP) and 
CpG (CpG-CNP)[10] (Yang et al. 2006). 
2.4 Animal vaccination   
Forty 21-day old healthy Landrace-York-Chuanbai hybrid piglets which were from a farm in Mianyang, China 
were randomly divided into four groups (A, B, C1 and C2), ten piglets per group and each piglet is about 4-5 kg. The 
groups A, B, C1 and C2 were respectively injected intramuscularly with 0.5 mg VPIL6C-CNP, VPIL6-CNP, CpG and 
VR1020-CNP (0.5 mg/piglet). Groups A and B were employed as the treated groups, groups C1 and C2 as the control 
groups (Table 1). Simultaneously, these four groups of piglets were intramuscularly inoculated with 2 ml attenuated 
Pseudorabies virus vaccines. 5 ml blood was collected from the piglets on 0, 7, 14, 28, 42 and 56 days after 
inoculation to assay the immunological changes. All pigs were bred under the same condition, and the initial and final 
weight of experimental pigs in each group were used to compare the effect of treatment on animal growth 
performance. The care and use of experimental piglets rationally complied with Chinese animal welfare laws, 
guidelines and regulations. 
Table 1 Groups of experimental piglets 
Group Treatment Dose (mg/piglet) 
A VPIL6C-CNP + vaccine, i.m 0.5 
B VPIL6-CNP + vaccine, i.m 0.5 
C1 CpG-CNP+ vaccine, i.m 0.5 
C2 VR1020-CNP + vaccine, i.m 0.5 
Note: CNP: chitosan nanoparticles; VR1020: a eukaryotic expression plasmid;  VPIL6: a recombinant eukaryotic 
VR1020 expression plasmid containing pig interleckin-6 gene; VPIL6C: VPIL6 inserted with the synthetic 
oligodeoxynucleotids with 11 CpG motifs; CpG: synthetic oligodeoxynucleotids with 11 CpG motifs. The followings 
are the same as here. i.m: intramuscular injection 
2.5. Immunological assay  
2.5.1 Assay of IgG, IgM and IgA-sandwich ELISA  
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Piglet IgG, IgM and IgA quantization ELISA Kits were purchased from Bethyl  Laboratory (Inc., America). The 
-well flat-bottomed plates were 
coated with capture antibody, goat anti-piglet IgG, IgM or IgA diluted in 100 ml of coating buffer (0.05 M sodium 
bicarbonate, pH 9.6); the plates were blocked and purified reference piglet serum was diluted at various concentrations 
to produce a standard curve. Serial dilutions of piglet serum samples were added and incubated.  After washing, goat 
anti-piglet secondary antibody labeled with horseradish peroxidase was applied. Antibody detection was completed 
with the addition of tetramethyl benzidine (TMB) substrate. Product formation was terminated by 2 M H2SO4 
solution. The OD value of the wells was determined at 450 nm by Microplate Reader 3550 (Bio-Rad, Hercules, 
California, US).  
2.5.2 Assay of interleukin 2, 4, 6 and interferon- sandwich ELISA 
The IL-2, IL-4, IL-6 and IFN-
IL-2, IL-4, IL-6 and IFN- ol. 
Briefly, the sera samples of experimental piglets were applied to the plates pre-coated with monoclonal antibody  to 
piglet IL-2, IL-4, IL-6 or IFN- -2, IL-4, IL-6 and IFN-
calibrating samples were respectively applied triplicate in twofold serial dilutions. The OD of the wells was measured 
at 450nm by Microplate Reader 3550 (Bio-Rad, Hercules, California, US), the wells without piglet serum were 
designated as negative control.  
2.5.3 Assay of specific antibody -SABC-ELISA 
The indirect ELISA was performed to assess the amount of anti-Pseudorabies virus antibody in the sera of piglets 
by use of antigenic proteins of Pseudorabies virus (provided by Chengdu Medicine and Appliances Factory, China). 
Flat-bottomed 96-well-plates (Nuclon, Roskilde, Denmark) were coated with the respective antigenic proteins (10 
with the sera of vaccinated piglets diluted 100-fold in sample diluent (pH7.4, 0.1 M PBS, 1% BSA). After incubation 
lated sheep anti-piglet IgG diluted 1:1200 was added to each well and 
incubated. Subsequently 100 ml strept-avidin biotin complex (SABC, Boster Company, Wuhan, China) diluted in 
1:1200 was added and incubated for 0.5 h at 37 C. Finally, 100 ml TMB substrate in 0.1 M phosphate citrate buffer 
O4 (50 ml/well) and the 
OD was measured by Microplate Reader 3550 (Bio-Rad, Hercules, California, US) at 450 nm.  
2.6 Counting of immune cell   
Briefly, the total number of leukocytes in the blood of piglets was counted as a routine method, and the blood smear 
were stained with Giemsa stain to sort out respectively the number of lymphocytes, monocytes and neutrophiles.      
2.7 Statistical analysis  
Data from all groups were presented as means ± SD, and statistically analyzed by the statistical software program 
Systat 10 (SPSS). Differences between the groups were analyzed by the two way ANOVA and Turkey multiple 
comparison. Data were considered to be significantly different if P<0.05.  
3. Results 
3.1. Preparation of chitosan nanoparticles 
Under the transmission electron microscope, most of CNP were spherical and the average granule diameter was 
160 nm (range from 95 to 270 nm), and analyzed by Zetasizer 3000 HS/IHPL,  the diversity of chitosan nanoparticles 
was 0.167, zeta potential was +19.52 mV, proving that the CNP was positively charged.  
3.2.  Humoral immune responses s to vaccine in the sera of the piglets 
3.2.1. Specific antibody response  
Fig. 1 shows the content of specific antibody to Pseudorabies virus in the piglets of groups A and B significantly 
raised from 7 to 56 days after inoculation compared with that of the controlled groups C1 and C2 (P<0.05), and the Ab 
content of group A was significant higher than that of group B from 7 to 56 days post-inoculation (P<0.05), but the 
difference was not remarkable between group C1 and group C2 (P>0.05). 
 
Figure. 1 Specific antibody responses to Pseudorabies vaccine in 
the sera of eperiemntal piglets. The content of specific antibody 
significantly increased in group A and B from 7 to 56 days after 
inoculation compared with that of the control C1 and C2 groups 
(P<0.05) , and the antibody content of group A was significantly 
higher than that of group B from 7 to 56 days post inoculation 
(P<0.05). All the groups were co-vaccinated with the same 
amount of attenuated Pseudorabies virus vaccine. The following 
are the same as here. 
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3.2.2. Immunoglobulin changes 
Fig.2 illustrates the content of IgG, IgM and IgA in the sera of treated piglets (A and B) was significant higher 
than that of controlled groups (C1 and C2) from 7 to 56 days after inoculation (P<0.05), and the difference between 
days after vaccination (P<0.05). The IgM content in group A was higher than group B from 14 to 28 days after 
inoculation (P<0.05). The IgA content in group A was higher than group B from 14 to 56 days after inoculation 
(P<0.05). And the difference between A and B about the amounts of IgG, IgM and IgA was not significant on other 
days (P>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.2 The change of the amounts of immunoglobulins in the 
sera of piglets after inoculation with Pseudorabies vaccines. a: The 
content of IgG significantly increased in the sera of groups A and 
B compared to groups C1 and C2 from 7 to 56 days after 
inoculation (P<0.05). b: The IgM content significantly increased  
in the sera of the treated piglets in comparion with group C1 and 
C2 from 7 to 56 days after inoculation (P<0.05). c: The content of 
IgA in the sera of of treated piglets was significantly higher than 
that of control C1 and C2 group from 7 to 56 days after inoculation 
(P<0.05), and so was the IgA content in group A compared to that 
of group B from 14 to 56 days after inoculation(P<0.05).  
3.3. Changes of IL-2, IL-4 IL-6 and INF-  
The results in Fig. 3 indicate that the contents of IL-2, IL-4, IL-6 and INF-
significantly increased in comparison with those of the control C1 and C2 group at different times post inoculation 
(P<0.05) but there was no obvious difference between C1 and C2 (P>0.05). The contents of IL-2 and IL-6 in the sera 
of piglets of group A was obviously higher than those of group B from 7 or 14 to 56 days after inoculation (P<0.05), 
and the level of INF-
group B. Whereas the difference of IL-4 content between group A and B was not significant (P>0.05). 
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Figure.3 The change of the concentration of cytokines in the sera of piglets. a: The content of IL-2 significantly 
rose in the sera of treated piglets in comparison with  that of group C1 and C2 from 7 to 56 days after inoculation 
(P<0.05). b: The content of IL-4 in the sera of piglets of treated piglets (A and B) was significant higher than that of 
group C1 and C2 from 7 to 56 days after inoculation (P<0.05), and the differences between group A and B were not 
remarkable, nor between C1 and C2 (P>0.05). c: The contents of IL-6 in the sera of group A and B were significant 
higher than those of group C1 and C2 from 7 to 56 days after inoculation (P<0.05), while the difference between 
group C1 and C2 was not notable  (P>0.05). d: The INF-  the treated piglets was significantly 
higher than that of group C1 and C2 from 7 to 56 days after inoculation (P<0.05), but the difference between groupA1 
and B was not notable (P>0.05). 
3.4. Changes of the number of immune cells 
The results in Fig. 4 demonstrate that the change of lymphocytes, granulocytes and monocytes in the blood of 
experiment piglets. The numbers of lymphocytes was significantly increased in the treated A and B piglets compared 
with the control C1 and C2 groups from 14 to 56 days post inoculation (P<0.05). The number of granulocytes showed 
no significant difference among all four groups (group A, B, C1 and C2) (P>0.05). And the amount of monocytes in 
the treated group were notably higher than that of the control groups from 14 to 28 days after inoculation (P<0.05). 
Meanwhile the significant difference neither appeared between A and B, nor between C1 and C2 (P>0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 4 The changes of immune cells in the blood of piglets 
inocualted with Pseudorabies vaccine. a: The numbers of 
lymphocytes increased significantly in the sera of vaccinated 
piglets in group A and B compared with that of the control 
groups from 14 to 56 days after vaccination (P<0.05). b: The 
numbers of granulocytes in the blood of piglets did not show 
significant differences among all four groups during the 
experiment period (P>0.05). c: The amounts of monocytes in 
group A and B were significantly higher than that of group 
C1 and C2 from 14 to 28 days after vaccination (P<0.05) 
(P>0.05). 
3.5. Effect on the growth performance of piglets 
The observation on growth performance of the pigs was initiated from day 1 to 56 day after the inoculation. The 
results showed that the weight gain of pigs in VRIL6C-CNP and VR6-CNP was evidently higher than that of the 
controls P<0.05, Table 2 .  
Table 2 Effect on the weight gain of experimental pigs during 56 days observation (n=10) 
Group Initial weight (kg) End weight (kg) Net gain (kg) Average gain (kg) 
A 4.85±0.53 37.52±1.86 32.67±1.63 0.583a 
B 4.78±0.61 36.65±1.42 31.87±1.75 0.569ab 
C1 4.92±0.62 34.56±2.18 29.64±1.56 0.529b 
C2 5.06±0.57 34.91±1.95 29.85±1.72 0.533b 
Note The data with the different superscript letter are significantly different (P<0.05) and vice versa (P>0.05).   
 
4. Discussion  
Recent reports have suggested that co-inoculation of DNA vaccine with immune- stimulatory molecules may 
significantly enhance Ag-specific immune responses in vivo. In order to trigger strong immune responses and provide 
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satisfactory protection against infectious diseases, adjuvant is usually required for different vaccines from 
conventional inactivated or attenuated vaccine to genetic recombinant protein and DNA vaccines. Normally, the 
current adjuvants include chemical molecules, derived bacteria and plant components and cytokines[11], but due to 
their different disadvantages, such as low bioactivity, short lasting time and possible serious side effects in vivo, ideal 
adjuvant with safer, more effective and more economical merits are still not available for the practical field application 
to control infectious diseases in animals.  
Bacterial DNA or oligodeoxynucleotides (ODN) containing CpG motifs are currently known not only to act as 
powerful adjuvant to elicit immune response against specific antigen [12], but also shift the immune responses 
substantially toward Th1 and modulated the Th1/Th2 immune response in DPT vaccine[13]. Recent researches have 
demonstrated that the immunostimulatory effect of CpG ODN is mainly dependent on the number and structure of 
CpG motifs in the cells and the correlated intracellular toll-like receptor 9, so the number and sequences of CpG 
motifs can decide the capability of ODN to trigger the immune reactions of animals.                                
In vitro, ODN containing CpG motifs can activate murine macrophages as demonstrated by their secretion of IL-
12, TNF- - - [14,15]. CpG ODNs are also mitogenic for B cells [16], can stimulate dendritic cells [17] 
and indirectly induce NK cells to secrete IFN- [18,19]. Interestingly, only the unique 
unmethylated CpG motifs could activate B cells, dendritic cells (DCs), NK T cells and monocytes to trigger an 
immune cascade that involves the production of cytokines and immunoglobulin [20,21]. 
In recent years, there were many reports about the immunostimulatory effect of CpG motifs as adjuvant, but most 
of them were focused on how to synthesize ODN and detect the effect of synthetic unmethylated CpG motifs on the 
immunity of animals to genetic protein and DNA vaccines. Moreover, the synthesis or PCR amplification of CpG 
motifs is expensive and time-costing, which is difficult to apply in the prevention of animal infectious diseases in large 
scale[22] . 
Interleukin-6 is a multifunctional cytokine and produced by a variety of cell types in both tissues of immune and 
endocrine systems [23]. It is extensively involved in promoting immune and haematopoietic bioactivities, such as 
interleukin gene expression, cell proliferation, B cell differentiation, T cell activation and neutrophil and macrophage 
differentiation[24]. Earlier researches had proved that PIL-6 gene could be correctly expressed in vivo and 
significantly enhanced the immune responses to pig vaccines in mice[8]. 
In order to achieve stronger promotion of the immunities of pig to viral vaccines and facilitate the cost-effective 
preparation of CpG motifs, the oligodeoxynucleotides with 11 CpG motifs were inserted into recombinant eukaryotic 
plasmids of pig IL-6 gene in our experiment, named as VPIL6C[26]. Our previous research once confirmed that 
VPIL6C could effectively enhance the humoral and cellular immune responses of mice to Pasteurella multocida and 
hog cholera vaccine [9]. Herein we further utilized VPIL6C to explore whether it could improve the immune 
responses of pig to viral vaccines as it did in mouse.  
It was firstly found in our present experiment that co-inoculation of only 0.5 mg of VPIL6C entrapped with CNP 
successfully induced stronger humoral and cellular immune responses in piglets to Pseudorabies vaccine. Compared 
with VPIL6 and CpG alone, the VPIL6C could significantly enhance the immunity in piglets to Pseudorabies vaccine, 
which was mirrored by the synergetic increases of specific antibody, immunoglobulin, IL-2, IL-6 and IFN- in the 
blood of piglets after vaccination. The examination of immune cells in the peripheral blood also showed that the 
lymphocytes and monocytes significantly increased in VPIL6C-CNP compared to the VPIL6-CNP group and the 
control groups (VR1020-CNP and CpG) post vaccination. All the results prove that VPIL6C-CNP can enhance the 
overall immune responses in piglets to vaccine. These results also suggest that synergetic immune effect between pig 
interleukin-6 gene and CpG motifs could be further applied to develop safer and better adjuvant to evoke stronger 
immune responses, which could be produced and inoculated by easy and cheap way in large scale in comparison with 
IL-6 gene and CpG motifs alone. 
Importantly, our experimental results confirmed that the naked CpG motifs failed to induce the notable 
improvement of immunities to Pseudorabies vaccines in piglets. The general immune responses in CpG treated piglets 
were not significantly better than those of the VR1020 control group during the all observation period(P<0.05), which 
could be probably attributed to the easy and fast digestion of CpG motifs by various nucleotides enzymes in vivo. On 
the contrary, the package of recombinant plasmids with chitosan nanoparticles was clearly successful, and the average 
diameter is 160 nm (range from 95 to 270 nm), truly suitable for preventing plasmids from the digestion by enzymes 
in vivo and promoting the penetration of plasmids into the cells in vivo. The encapsulation of plasmids and CpG motifs 
would effectively block the combination of various enzymes with DNA molecules and prevent the damage by the 
digestion in vivo [25].  
Furthermore, besides the significant promotion of humoral and cellular immunity to vaccine, the VPIL6C-CNP did 
not cause any detectable side effects in piglets in our experiments, such as local injuries in the injection sites and 
systemic fever. In contrast, the VPIL6C-CNP inoculation resulted in obvious improvement of growth performance of 
piglets in comparison with those of control animals, implying the effectiveness of VPIL6C-CNP as a safe 
immunoadjuvant for pig in the future.  
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Briefly, our experimental results proved that VPIL6C-CNP could significantly enhance the immune responses in 
piglets to Pseudorabies vaccines, and the combination of pig IL-6 gene with CpG motifs not only promote the immune 
resistance of animal, but also facilitate the preparation of safe and effective adjuvant through fermentation in large 
scale, which is critical for extensive practical utilization of molecular adjuvant to control infectious diseases of pigs in 
the future.  
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